肝细胞癌切除术前应用肝动脉化疗栓塞术疗效的Meta分析

高胜; 刘剑勇; 张志明; 赵荫农; 袁卫平; 吴飞翔; 向邦德

doi:10.3969/j.issn.1001-5256.2014.09.020

肝细胞癌切除术前应用肝动脉化疗栓塞术疗效的Meta分析

DOI: 10.3969/j.issn.1001-5256.2014.09.020

广西医科大学附属肿瘤医院肝胆外科

基金项目:

广西医疗卫生重点科研课题(重200611)；广西科学基金项目(桂科自0728196)；广西科学研究与技术开发计划项目(桂科攻0719006-2-5)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2530
- HTML全文浏览量: 18
- PDF下载量: 611
- 被引次数: 0
出版历程
- 收稿日期: 2013-12-30
- 出版日期: 2014-09-20

Efficacy of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma before hepatectomy:a meta-analysis

Department of Hepatobiliary Surgery, Tumor Hospital of Guangxi Medical University

Research funding:

摘要

摘要:
目的旨在评价肝动脉化疗栓塞术(TACE)在肝细胞癌(HCC)切除术前应用的疗效。方法计算机检索PubMed、Embase、Cochrane library、CNKI、VIP、万方数据库,截止日期到2013年3月12日。收集公开发表的关于HCC切除术前TACE治疗与单纯手术治疗比较的随机对照试验,对纳入的文献进行资料提取和质量评价,采用ReMan5.2软件进行统计分析。结果共纳入4个随机对照试验,共342例患者。Meta分析结果显示:术前TACE组与单用手术切除治疗HCC组相比,术后1、3、5年无瘤生存率的相对危险度(RR)[95%可信区间(CI)]分别为1.07(0.92~1.25)(P=0.38)、1.05(0.79~1.41)(P=0.72)、0.95(0.64~1.42)(P=0.81);1、3、5年总生存率的RR(95%CI)分别为1.01(0.92~1.10)(P=0.85)、1.14(0.97~1.34)(P=0.11)、0.95(0.75~1.21)(P=0.68);术后并发症发生率及病死率合并分析其相对危险度的RR(95%CI)分别为0.89(0.45~1.75)(P=...
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 肝切除术 /
- Meta分析
Abstract:
Objective To assess the efficacy of transcatheter arterial chemoembolization ( TACE) in patients with hepatocellular carcinoma ( HCC) before hepatectomy. Methods PubMed, Embase, the Cochrane Library, CNKI, VIP, and Wanfang Data were searched to identify randomized controlled trials ( RCTs) evaluating the efficacy of preoperative TACE plus hepatectomy ( study group) versus hepatectomy alone ( control group) in HCC patients published up to March 12, 2013. The quality of included studies was assessed, and relevant data were extracted. Statistical analysis was performed by RevMan 5. 2. Results A total of 4 RCTs involving 342 participants were included. Meta- analysis of data extracted from the included RCTs showed that there were no significant differences between the study group and control group in 1-, 3-, and 5- year disease- free survival ( DFS) , with relative risks ( RRs) ( 95% confidence intervals ( CIs) ) of 1. 07 ( 0. 92-1. 25) ( P = 0. 38) , 1. 05 ( 0. 79, 1. 41) ( P = 0. 72) , and 0. 95 ( 0. 64- 1. 42) ( P = 0. 81) , respectively, in 1-, 3-, and 5- year overall survival ( OS) , with RRs ( 95% CIs) of 1. 01 ( 0. 92- 1. 10) ( P = 0. 85) , 1. 14 ( 0. 97- 1. 34) ( P = 0. 11) , and 0. 95 ( 0. 75-1. 21) ( P = 0. 68) , respectively, and in rate of postoperative complications and mortality, with RRs ( 95% CIs) of 0. 89 ( 0. 45- 1. 75) ( P= 0. 73) and 0. 77 ( 0. 25- 2. 37) ( P = 0. 65) , respectively. Conclusion TACE before hepatectomy cannot increase DFS and OS and reduce complications and mortality in HCC patients. However, the numbers of studies and cases included in the analysis are small, and more high- quality, large- sample RCTs are needed to confirm the conclusion.
- carcinoma, hepatocellular /
- chemoembolization, therapeutic /
- hepatectomy /
- meta-analysis

HTML全文

参考文献(19)

[1]WU CC, HO YZ, HO WL, et al.Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma:a reappraisal[J].Br J Surg, 1995, 82 (1) :122-126.

[2]YAMASAKI S, HASEGAWA H, KINOSHITA H, et al.A prospective randomizedtrial of preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma[J].Jpn J Cancer Res, 1996, 87 (2) :206-211.

[3] ZHOU WP, LAI EC, LI AJ, et al.A prospective, randomized, controlled trial of preoperative transartefial chemoembolization for resectable large hepatocellular carcinoma[J].Ann Surg, 2009, 249 (2) :195-202.

[4] KAIBORI M, TANIGAWA N, KARIYA S, et al.A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma[J].Dig Dis Sci, 2012, 57 (5) :1404-1412.

[5] LLOVET JM, SCHWARTZ M, MAZZAFERRO V, et al.Resection and liver transplantation for hepatocellular carcinoma[J].Semin Liver Dis, 2005, 25 (2) :181-200.

[6] KOW AW, KWON CH, SONG S, et al.Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma:review of 1222 cases of hepatectomy in a tertiary institution[J].Ann Surg Oncol, 2012, 19 (7) :2246-2255.

[7] HO CM, WU CY, LEE PH, et al.Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma[J].Ann Surg Oncol, 2013, 20 (8) :2526-2533.

[8]BREEDIS C, YOUNG Y.The blood supply of neoplasms inthe liver[J].Am J Pathol, 1954, 30 (5) :969-977.

[9]WANG ZX, LI HQ, WANG ZT.The significance of surgery combined with interventional therapy in primary hepatic carcinoma[J].J Med Imaging, 2009, 19 (8) :987-989. (in Chinese) 王振旭, 李红旗, 王振亭.原发性肝癌外科手术联合血管内介入治疗的意义[J].医学影像学杂志, 2009, 19 (8) :987-989.

[10]PU J, WEI ZH, WANG JC, et al.The value of preoperative transcatherter arterial chemoembolization in reducing the lesion-residual rate after hepatecomy of primary hepatocellular carcinoma[J].J Pract Radiol, 2006, 22 (4) :446-452. (in Chinese) 浦涧, 韦忠恒, 汪建初, 等.术前肝动脉化疗栓塞对减少原发性肝癌手术癌残存的意义[J].实用放射学杂志, 2006, 22 (4) :446-452.

[11] SUGO H, FUTAGAWA S, BEPPU T, et al.Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma:relation between postoperative course and the pattern of tumor recurrence[J].World J Surg, 2003, 27 (12) :1295-1299.

[12]LU CD, PENG SY, JIANG XC, et al.Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinomas:retrospective analysis of 120 cases[J].World J Surg, 1999, 23 (3) :293-300.

[13]ZHANG B, WU LQ.Evaluation of treatment of primary liver cancer-transcatheter arterial chemoembolization before and after hepatectomy in treatment of primary liver cancer[J].Shangdong Med J, 2003, 43 (36) :56. (in Chinese) 张斌, 吴力群.肝切除术前后肝动脉置管化疗栓塞治疗原发性肝癌[J].山东医药, 2003, 43 (36) :56.

[14]YU WS, GUO RP, SHI M, et al.Efficacy of second stage resection following transcatheter hepatic arterial chemoembolization in patients with large hepatocellular carcinoma of hardly radical excision[J].J Sun Yat-Sen Univ:Medical Sciences, 2007, 28 (6) :709-713. (in Chinese) 俞武生, 郭荣平, 石明, 等.难以根治性切除大肝癌经皮肝动脉化疗栓塞术后二期切除的疗效分析[J].中山大学学报:医学科学版, 2007, 28 (6) :709-713.

[15]ZHOU JP, ZHOU WP, CONG WM, et al.Pathological study of resected specimens of resectable large hepatocellular carcinoma after transcatheter arterial chemoembolization[J].J Hepatobiliary Surg, 2004, 12 (1) :11-13. (in Chinese) 周建平, 周伟平, 丛文铭, 等.大肝癌TACE后手术切除标本的病理研究[J].肝胆外科杂志, 2004, 12 (1) :11-13.

[16]ZHU WB, LI CL, FANG XJ, et al.Preventive effects of perioperative transarterial chemoembolization on recurrence of large hepatocellular carcinoma[J].Chin J Hepatobiliary Surg, 2001, 7 (4) :208-230. (in Chinese) 朱玮冰, 李朝龙, 方学军, 等.围手术期肝动脉栓塞化疗预防大肝癌术后复发的作用初探[J].中华肝胆外科杂志, 2001, 7 (4) :208-230.

[17]LUO YQ, WANG Y, CHEN H, et al.Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma[J].Chin J Gen Surg, 2002, 17 (3) :149-151. (in Chinese) 罗运权, 王义, 陈汉, 等.可切除肝癌术前经肝动脉化学药物栓塞对肝切除手术的影响[J].中华普通外科杂志, 2002, 17 (3) :149-151.

[18] HARADA T, MATSUO K, INOUE T, et al.Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?[J].Ann Surg, 1996, 224 (1) :4-9.

[19]HUANG J, HE X, LIN X, et al.Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma[J].Chin Med J (Engl) , 2000, 113 (5) :446-448.引证本文:GAO S, LIU JY, ZHANG ZM, et al.Efficacy of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma before hepatectomy:a meta-analysis[J].J Clin Hepatol, 2014, 30 (9) :917-920. (in Chinese) 高胜, 刘剑勇, 张志明, 等.肝细胞癌切除术前应用肝动脉化疗栓塞术疗效的Meta分析[J].临床肝胆病杂志, 2014, 30 (9) :917-920.

施引文献

资源附件(0)

访问统计